Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Is Eli Lilly and Company the Largest Publicly Traded Healthcare Company?

In this article, we will be taking a look at is Eli Lilly and Company the largest publicly traded healthcare company? If you wish to learn about more companies, head straight to the Top 20 Largest Publicly Traded Healthcare Companies.

Major Players Driving the U.S. Healthcare Industry’s Growth and Innovation

The global healthcare industry is a massive and rapidly growing sector, valued at around $7.975 trillion as of 2023. According to the World Health Organization (WHO), at least half of the world’s population lacks access to essential health services. The U.S. healthcare industry is one of the largest and most complex in the world, accounting for nearly 20% of the country’s GDP. In 2021, the U.S. healthcare industry was worth $808 billion, with 65% of the revenue coming from patient care. However, the COVID-19 pandemic caused a significant drop in revenue, with the U.S. healthcare system’s revenue declining by around 50% in 2020.

Several healthcare companies play an important role in the US health industry. These companies include CVS Health Corporation (NYSE:CVS), Johnson & Johnson (NYSE:JNJ), and Pfizer, among others.

CVS Health Corporation (NYSE:CVS) is a leading healthcare company in the United States, with over 9,000 retail locations across the United States. CVS Health’s PBM business helps manage prescription drug costs for millions of Americans, making medications more affordable and accessible. CVS Health Corporation (NYSE:CVS)’s total revenues increased 11.9% to $93.8 billion in Q4,2023 and the total revenues increased 10.9% to $357.8 billion for the full year.

Similarly, Johnson & Johnson (NYSE:JNJ) also play an important role in US healthcare. It is one of the largest healthcare stocks in the US. Johnson & Johnson (NYSE:JNJ) developed the first single-dose COVID-19 vaccine (Janssen COVID-19 Vaccine) in 2020. A large priority R&D pipeline with 64 projects, including 19 late-stage candidates targeting priority diseases like HIV/AIDS, tuberculosis, and viral hepatitis. All 19 late-stage candidates have access plans in place for low- and middle-income countries (LMICs). Commitment to supporting the control of soil-transmitted helminthiasis through mebendazole (Vermox) donations until 2025 in 51 countries. Johnson & Johnson (NYSE:JNJ)’s Q1 2024 reported sales grew 2.3% to $21.4 billion, with operational growth of 3.9% and adjusted operational growth of 4.0%. In the U.S., sales surged 7.8% to $11.6 billion in the same period.

The Booming Telemedicine Market and Rising Healthcare Costs: Global and U.S. Perspectives

One of the innovations that is most revolutionizing the field of digital health is telemedicine. With a predicted CAGR of 17.2% between 2023 and 2030, the global telemedicine market, which was valued at $87.41 billion in 2022, is projected to grow to $286.22 billion by 2030. With China aiming to build 20,000 hospitals in the next ten years to improve access to healthcare, global healthcare spending outside the US is predicted to expand more quickly than within the US. Considerable investment opportunities arise from rising medical inflation in the private sector in Brazil, where 75% of the population is covered by universal health care.

The expense of healthcare has been rapidly rising in the US. Everything increased in price by almost 81% between June 2023 and 2000, while healthcare expenditures increased by 114%. The COVID-19 epidemic has exacerbated the situation. COVID is becoming more and more like the flu, but treating and preventing it still comes with a high price tag. According to estimates from McKinsey, the US will pay an additional $200 billion annually on healthcare linked to COVID-19.

A robotic arm picking up a product assembly line, displaying the company’s consumer healthcare and wellness offerings.

Our Methodology  

For our methodology, we have ranked the top largest publicly traded healthcare companies based on their current market caps. For the accuracy of data, we relied on Yahoo Finance.

The largest publicly traded healthcare company is Eli Lilly and Company (NYSE:LLY).

1. Eli Lilly and Company (NYSE:LLY)

Market Cap: $763.33 Billion 

Eli Lilly and Company ranks first on our list for being the largest publicly traded healthcare company. In Q1 2024, Their worldwide revenue was $8.77 billion, up 26% from Q1 2023, driven by 16% volume growth and 10% higher realized prices. The revenue growth was mainly led by strong sales of Mounjaro, Zepbound, Verzenio, and Jardiance.

You can take a look at the rest of the rankings here.

You can also check out the 20 Most Valuable Healthcare Companies in the World. 

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!